Nyural was founded on the belief that everyone should have access to information about their own health, particularly in the field of neurodegenerative diseases. Our AI-powered risk assessment empowers individuals to take proactive measures in managing their neurological health. By leveraging advanced AI models and a comprehensive genetic dataset, we provide highly accurate and personalized risk assessments that far surpass traditional methods.
Nyural的外部链接
US，Ohio，Cleveland
Nyural转发了
Northeastern University | Founder & Lead Director @ IntersectSTEM | Founder, COO @ Nyural
I am very proud to announce that my research titled "Using Machine-Learning to Generate Complex Polygenic Risk Scores for Alzheimer's" was accepted and invited for oral presentation at the World Neuroscience Conference, 2025 in Amsterdam, Netherlands. I am extremely excited to keep working on this research and sharing it with modern science and medicine!
Nyural转发了
I'm very excited to announce that my research entitled "Using Machine-learning to Generate Complex Polygenic Risk Scores for Alzheimer’s Disease" was accepted by the International Neuroscience Conference and invited to give an oral presentation in Amsterdam sharing the work. I look forward to the implications of this research and and can't wait to keep working on it.
Just today, Eli Lilly's drug Donanemab (Kisunla) was approved by the FDA as a means to slow the progression of Early-Onset Alzheimer's. This approval marks a critical milestone in the fight against a disease that has long avoided treatment. Donanemab is the latest in a series of promising developments. It follows the approval of Lecanemab (Leqembi) by the FDA last year, another monoclonal antibody designed to slow the progression of Alzheimer's. Both Donanemab and Lecanemab target amyloid plaques, abnormal protein deposits in the brain that are characteristic of Alzheimer's disease. By addressing these plaques, these drugs aim to decelerate the cognitive decline associated with the condition. Despite these advancements, Alzheimer's remains a major problem. Aside from being incurable, its prevalence continues to rise, expected to affect 14 million people by 2050. While new treatments offer hope and can improve quality of life by slowing disease progression, they aren't as effective as preventing the onset of the disease in the first place. Through our risk assessments we seek to provide individuals with the information and lifestyle habits they need to either avoid the disease in the first place, or to get treatment as early as possible. If you want to learn more or join our waitlist, check out our website: www.nyural.ai